The Changing Face of Parkinsonian Neurodegeneration

Česká verzia

Authors: K. Menšíková ¹; P. Kaňovský ¹; M. Kaiserová ¹; I. Nestrašil ²; M. Bareš ³
Authors place of work: Neurologická klinika LF UP a FN Olomouc ¹; Department of Neurology and Brain Sciences Center, University of Minnesota, MN, USA ²; I. neurologická klinika LF MU a FN u sv. Anny v Brně ³
Published in the journal: Cesk Slov Neurol N 2013; 76/109(1): 26-34
Category: Review Article

Summary

Parkinson’s disease continues to be described as a relatively homogenous nosological entity, characterised by the presence of four cardinal signs – bradykinesia, rigidity, tremor and postural instability – with a variable presence of other motor and non-motor symptoms (cognitive, behavioral, vegetative etc.); its pathological basis being the continuous progression of brain alpha-synucleinopathy. It seemed that this clinical entity might be relatively easily diagnosed using the United Kingdom Parkinson’s Disease Brain Bank (UK--PDBB) clinical diagnostic criteria that are based on the results of a retrospective clinical and pathological study. However, substantial opinion shift occurred as a result of the recent intensive field research. A distinction has arbitrarily been made between Dementia with Lewy bodies and Parkinson’s disease dementia. Several next mutations (PARK10–PARK13, PARK16–PARK18) encoding the manifestation of “sporadic“, late-onset and typical Parkinson’s disease have been added to the existing spectrum of familiar Parkinson’s disease. Therefore, the term “Parkinson’s disease” should be used for the “sporadic” form of the disease only. However, for the “definite” or “highly probable” level of diagnostic accuracy, the UK-PDBB criteria are less useful. The term “neurodegenerative Parkinsonism” would probably better reflect current level of diagnostic certainty referring to Parkinson’s disease.

Key words:
Parkinson’s disease – hereditary parkinsonism – neurodegenerative parkinsonism

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE “uniform requirements” for biomedical papers.

Zdroje

1. McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65(12): 1863–1872.

2. Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, MizunoY et al. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Mov Disord 2007; 22(12): 1689–1707.

3. Uc EY, Rodnitzky RI. Juvenile parkinsonism. Semin Pediatr Neurol 2003; 10(1): 62–67.

4. Calne SM, Kumar A. Young onset Parkinson’s disease. Practical management of medical issues. Parkinsonism Relat Disord 2008; 14(2): 133–142.

5. Thomsen TR, Rodnitzky RI. Juvenile parkinsonism: epidemiology, diagnosis and treatment. CNS Drugs 2010; 24(6): 467–477.

6. Nussbaum R, Polymeropoulos M. Genetics of Parkinson’s disease. Hum Mol Genet 1997; 6(10): 1687–1691.

7. Foroud T, Uniacke SK, Liu L, Pankratz N, Rudolph A, Halter C et al. Heterozygosity for a mutation in the parkin gene leads to later onset Parkinson disease. Neurology 2003; 60(5): 796–801.

8. Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S et al. Alpha-synuclein locus duplication as a cause of familial Parkinson’s disease. Lancet 2004; 364(9440): 1167–1169.

9. Mata IF, Lockhart PJ, Farrer MJ. Parkin genetics: one model for Parkinson’s disease. Hum Mol Genet 2004; 13(1): R127–R133.

10. Eriksen J, Wsolek Z, Petrucelli J. Molecular pathogenesis of Parkinson disease. Arch Neurol 2005; 62(3): 353–357.

11. Hicks AA, Pétursson H, Jónsson T, Stefánsson H, Jóhannsdóttir HS, Sainz J et al. A susceptibility gene for late-onset idiopathic Parkinson’s disease. Ann Neurol 2002; 52(5): 549–555.

12. Gasser T. Mendelian forms of Parkinson’s disease. Biochim Biophys Acta 2009; 1792(7): 587–596.

13. Corti O, Lesage S, Brice A. What genetics tells us about the causes and mechanisms of Parkinson’s disease. Physiol Rev 2011; 91(4): 1161–1218.

14. Schrag A, Ben-Shlomo Y, Quinn NP. Cross sectional prevalence survey of idiopathic Parkinson’s disease and Parkinsonism in London. BMJ 2000; 321(7252): 21–22.

15. Quinn N, Critchley P, Marsden CD. Young onset Parkinson’s disease. Mov Disord 1987; 2(2): 73–91.

16. Butterfield PG, Valanis BG, Spencer PS, Lindeman CA, Nutt JG. Environmental antecedents of young-onset Parkinson’s disease. Neurology 2006; 43(6): 1150–1158.

17. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A et al. Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 1997; 276(5321): 2045–2047.

18. Healy DG, Abou-Sleiman PM, Wood NW. PINK, PANK or PARK? A clinicans guide to familial parkinsonism. Lancet Neurol 2004; 3(11): 652–662.

19. Spira PJ, Sharpe DM, Halliday G, Cavanagh J, Nicholson GA. Clinical and pathological features of a Parkinsonian syndrome in a family with an Ala53ThR alpha-synuclein mutation. Ann Neurol 2001; 49(3): 313–319.

20. Samii A, Markopoulou K, Wszolek ZK, Sossi V, Dobko T, Mak E et al. PET studies of parkinsonism associated with mutation in the alpha-synuclein gene. Neurology 1999; 53(9): 2097–2102.

21. Zarranz JJ, Alegre J, Gómez-Esteban JC, Lezcano E, Ros R, Ampuero I et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 2004; 55(2): 164–173.

22. Hedrich K, Marder K, Harris J, Kann M, Lynch T, Meija-Santana H et al. Evaluation of 50 probands with early-onset Parkinson’s disease for Parkin mutations. Neurology 2002; 58(8): 1239–1246.

23. Khan NL, Graham E, Critchley P, Schrag AE, Wood NW, Lees AJ et al. Parkin disease: a phenotypic study of a large case series. Brain 2003; 126(Pt 6): 1279–1292.

24. Khan NL, Katzenschlager R, Watt H, Bhatia KP, Wood NW, Quinn N et al. Olfaction differentiates parkin disease from early-onset parkinsonism and Parkinson disease. Neurology 2004; 62(7): 1224–1226.

25. Farrer M, Chan P, Chen R, Tan L, Lincoln S, Hernandez D et al. Lewy bodies and parkinsonism in families with parkin mutations. Ann Neurol 2001; 50(3): 293–300.

26. Gasser T, Müller-Myshok B, Wszolek ZK, Oehlmann R, Calne DB, Bonifati V et al. A susceptibility locus for Parkinson’s disease maps to chromosome 2p13. Nat Genet 1998; 18(3): 262–265.

27. Klein C, Vieregge P, Hagenah J, Sieberer M, Doyle E, Jacobs H et al. Search for the PARK3 founder haplotype in a large cohort of patients with Parkinson’s disease from northern Germany. Ann Hum Genet 1999; 63(Pt 4): 285–291.

28. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J et al. Alpha-synuclein locus triplication causes Parkinson’s disease. Science 2003; 302(5646): 841.

29. Gwinn K, Devine M, Jin LW, Johnson J, Bird T, Muenter M et al. Clinical features, with video documentation, of the original familial Lewy body Parkinsonism caused by alpha-synuclein triplication (lowa kindred). Mov Disord 2011; 26(11): 2134–2136.

30. Healy DG, Abou-Sleiman PM, Wood NW. Genetic causes of Parkinson’s disease: UCHL-1. Cell Tissue Res 2004; 318(1): 189–194.

31. Leroy E, Boyer R, Auburger G, Leube B, Ulm G, Mezey E et al. The ubiquitin pathway in Parkinson’s disease. Nature 1998; 395(6701): 451–452.

32. Maraganore DM, Lesnick TG, Elbaz A, Chartier--Harlin MC, Gasser T, Krüger R et al. UCHL1 is a Parkinson’s disease susceptibility gene. Ann Neurol 2004; 55(4): 512–521.

33. Valente EM, Abou-Sleiman PM, Caputo V, Muqit MM, Harvey K, Gispert S et al. Hereditary early-onset Parkinson’s disease caused by mutations in PINK1. Science 2004; 304(5674): 1158–1160.

34. Bonifati V, Rohé CF, Breedveld GJ, Fabrizio E, De Mari M, Tassorelli C et al. Early-onset parkinsonism associated with PINK-1 mutations: frequency, genotypes and phenotypes. Neurology 2005; 65(1): 87–95.

35. Bonifati V, Rizzu P, van Baren MJ, Schaap O, Breedveld GJ, Krieger E et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003; 299(5604): 256–259.

36. Dekker M, Bonifati V, van Swieten J, Leenders N, Galjaard RJ, Snijders P et al. Clinical features and neuroimaging of PARK-7-linked parkinsonism. Mov Disord 2003; 18(7): 751–757.

37. Paisán-Ruíz C, Jain S, Evans EW, Gilks WP, Simón J, van der Brug M et al. Cloning of the gene containing mutations that cause PAR8-linked Parkinson’s disease. Neuron 2004; 44(4): 595–600.

38. Aasly JO, Toft M, Fernandez-Mata I, Kachergus J, Hulihan M, White LR et al. Clinical features of LRRK-2 associated Parkinson’s disease in central Norway. Ann Neurol 2005; 57(5): 762–765.

39. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S et al. Mutations in LRRK-2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004; 44(4): 601–607.

40. Williams DR, Hadeed A, al-Din AS, Wreikat AL, Lees AJ. Kufor Rakeb disease: autosomal recessive, levodopa-responsive parkinsonism with pyramidal degeneration, supranuclear gaze palsy and dementia. Mov Disord 2005; 20(10): 1264–1271.

41. Ramirez A, Heimbach A, Gründemann J, Stiller B, Hampshire D, Cid LP et al. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet 2006; 38(10): 1184–1191.

42. Schneider SA, Paisan-Ruiz C, Quinn NP, Lees AJ, Houlden H, Hardy J et al. ATP13A2 mutations (PARK9) cause neurodegeneration with brain iron accumulation. Mov Disord 2010; 25(8): 979–984.

43. Hicks AA, Pétursson H, Jónsson T, Stefánsson H, Jóhannsdóttir HS, Sainz J et al. A susceptibility gene for late-onset idiopathic Parkinson’s disease. Ann Neurol 2002; 52(5): 549–555.

44. Haugarvoll K, Toft M, Ross OA, Stone JT, Heckman MG, White LR et al. ELAVL4, PARK10 and the Celts. Mov Disord 2007; 22(4): 585–587.

45. Pankratz N, Nichols WC, Uniacke SK, Halter C, Rudolph A, Shults C et al. Significant linkage of Parkinson disease to chromosome 2q36-q37. Am J Hum Genet 2003; 72(4): 1053–1057.

46. Pankratz N, Nichols WC, Uniacke SK, Halter C, Murrell J, Rudolph A et al. Genome-wide linkage analysis and evidence of gene-by-gene interactions in a sample of 362 multiplex Parkinson disease families. Hum Mol Genet 2003; 12(20): 2599–2608.

47. Strauss KM, Martins LH, Plun-Favreau H, Marx FP, Kautzmann S, Berg D et al. Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson’s disease. Hum Mol Genet 2005; 14(15): 2099–2111.

48. Yoshino H, Tomiyama H, Tachibana N, Ogaki K, Li Y, Funayama M et al. Phenotypic spectrum of patients with PLA2G6 mutation and PARK14-linked parkinsonism. Neurology 2010; 75(15): 1356–1361.

49. Paisán-Ruiz C, Guevara, R, Federoff M, Hanagasi H, Sina F, Elahi E et al. Early-onset L-dopa-responsive parkinsonism with pyramidal signs due to ATP13A2, PLA2G6, FBX07 and spatacsin mutations. Mov Disord 2010; 25(12): 1791–1800.

50. Mata IF, Yearout D, Alvarez V, Coto E, de Mena L, Ribacoba R et al. Replication of MAPT and SNCA, but not PARK16–18, as susceptibility genes for Parkinson’s disease. Mov Disord 2011; 26(5): 819–823.

51. Sundal C, Fujioka S, Uitti R, Wszolek Z. Autosomal dominant Parkinson’s disease. Parkinsonism Relat Disord 2012; 18 (Suppl 1): S7–S10.

52. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuarcy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55(3): 181–184.

53. Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. What features improve accuracy of clinical diagnosis in Parkinson’s disease: a clinicopathologic study. Neurology 1992; 42(6): 1142–1146.

54. Hughes AJ, Daniel SE, Blankson S, Lees AJ. A clinicopathologic study of 100 cases of Parkinson’s disease. Arch Neurol 1993; 50(2): 140–148.

55. Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson’s disease. Neurology 2001; 57(8): 1497–1499.

56. Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialis movement disorder service. Brain 2002; 125(Pt 4): 861–870.

57. Braak H, Ghebremedhin E, Rüb U, Bratzke H, Del Tredici K. Stages in the development of Parkinson’s disease-related pathology. Cell Tissue Res 2004; 318(1): 121–134.

58. Braak H, Müller CM, Rüb U, Ackermann H, Bratzke H, de Vos RA et al. Pathology associated with sporadic Parkinson’s disease – where does it end? J Neural Transm Suppl 2006; 70: 89–97.

59. Galpern WR, Lang AE. Interface between tauopathies and synucleinopathies: a tale of two proteins. Ann Neurol 2006; 59(3): 449–458.

60. Badiola N, de Oliveira RM, Herrera F, Guardia--Laquarta C, Concalves SA, Pera M et al. Tau enhances alpha-synuclein aggregation and toxicity in cellular models of synucleinopathy. PLoS One 2011; 6(10): e26609.

61. Jellinger K. Interactions between alpha-synuclein and other proteins in neurodegenerative disorders. Scientific World Journal 2011; 11: 1893–1907.

62. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson’s disease. Arch Neurol 1999; 56(1): 33–39.

63. Fiala O, Růžička E. Genetika Parkinsonovy nemoci. Cesk Slov Neurol N 2009; 72/105(5): 419–428.

64. Petrleničová D, Gmitterová K, Benetin J. Mechanizmy neurodegenerácie pri Parkinsonovej chorobe. Cesk Slov Neurol N 2010; 73/106(6): 645–649.

65. Kračunová K, Kovačovičová M, Baldovič P, Valkovič P, Kádaši Ľ, Benetin J. Výskyt mutácií v géne Leucine rich repeate kinase 2 u pacientov s Parkinsonovou chorobou na Slovensku. Cesk Slov Neurol N 2011; 74/107(4): 443–445.

66. Stern MB, Lang A, Poewe W. Toward a redefinition of Parkinson’s disease. Mov Disord 2012; 27(1): 54–60.

67. Jellinger K. Neuropathology of sporadic Parkinson’s disease: evaluation and changes of concepts. Mov Disord 2012; 27(1): 8–30.